Search the Newsreel

How Euronet’s CoreCard Deal and ESOP Shelf Filing Could Reshape Euronet Worldwide (EEFT) Investors’ Focus

Euronet Worldwide (EEFT) recently signed a multi-year SaaS agreement with Unibanca to deploy its CoreCard platform in Peru and filed a US$152.08 million ESOP shelf registration. The Unibanca deal emphasizes Euronet's strategy to expand software-driven payments and credit issuing, reinforcing its investment narrative amidst …

Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding

Alto Neuroscience (ANRO) saw a 13.5% stock increase after expanding its ALTO-207 Phase 3 trial for treatment-resistant depression and securing approximately $100 million in new funding. Despite ongoing net losses, the company aims to validate its data-driven approach, with short-term focus on the expanded …

Walleye Trading LLC Makes New Investment in Euronet Worldwide, Inc. $EEFT

Walleye Trading LLC has made a new investment in Euronet Worldwide (NASDAQ:EEFT), purchasing 14,588 shares valued at approximately $1.07 million. Other institutional investors also adjusted their holdings, with a significant 91.6% of the stock owned by institutional investors and hedge funds. Analyst sentiment for …

Euro India Fresh Foods Ltd is Rated Sell

Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen

Wall Street Zen upgraded Alto Neuroscience (NYSE:ANRO) from "strong sell" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with a target price of $36.62. Shares opened at $32.14, near their 12-month high, and the company reported a quarterly loss of $0.65 …

EUROPAP TEZOL KAGIT Hisse Senedi Canlı Grafik

Euroseas (ESEA) Stock Shrugs Off Heavy Profits As Funding Questions Linger

Euroseas (ESEA) reported strong Q2 2026 earnings with increased net income and EPS, yet its stock price remained largely flat. This indicates market skepticism regarding the sustainability of its profitability, possibly due to concerns about funding for a large newbuild program and the age …

NeuroPace (NPCE): OrbiMed reports 1.51M-share, 4.4% beneficial stake

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have reported an amended beneficial ownership stake in NeuroPace Inc. (NPCE). The entities collectively own 1,505,125 shares, representing 4.4% of NeuroPace's common stock as of June 30, 2026, and share both voting and dispositive power …

Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap

An investor group comprising Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. has reported a beneficial ownership of 9.99% in Alto Neuroscience (ANRO). This ownership, totaling 4,176,711 shares, includes common stock and pre-funded warrants, with the exercise of warrants capped …

EURO TREND YAT. ORT. (ETYAT) Hisse Senedi

Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A

Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership in Alto Neuroscience, Inc., totaling 785,000 shares. These shares are held through a fund and a managed account advised by Vestal Point Capital, with both shared …

Point72 discloses 5% Neuronetics (STIM) stake in new SEC ownership filing

Point72 Asset Management, L.P., along with Point72 Capital Advisors, Inc., and Steven A. Cohen, has reported a beneficial ownership of 5.0% of Neuronetics, Inc.'s common stock, totaling 3,822,124 shares as of August 13, 2026. This disclosure was made in a new SEC ownership filing …

Price to earnings ratio of European Green Transition Plc – LSE:EGT

EURO KAPITAL YAT. ORT. (EUKYO) Hisse Senedi

Euroseas posts $33.2 million Q2 profit, expands newbuilding programme

Euroseas reported a net income of $33.2 million in Q2 2026, driven by strong containership charter rates and low drydocking expenses, making it one of the company's most profitable quarters in 15 years. The company has expanded its newbuilding program to 12 feeder and …

Euro Sun Mining Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside

Alto Neuroscience, Inc. (ANRO) has seen its average 12-month price target increased to $37.56 by 9 analysts, suggesting a 16% potential upside from its August 13 closing price. The consensus rating for the stock remains a "Buy" from 11 analysts.

Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says

Guggenheim raised its price target for Promis Neurosciences (NASDAQ:PMN) from $69 to $100, maintaining a "Buy" rating, while other analysts have varied ratings but a consensus "Moderate Buy" with a $39.25 target. The clinical-stage biopharmaceutical company's shares opened at $14.93, with a market capitalization …

ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside

ProMIS Neurosciences Inc. (PMN) has seen its 12-month average price target raised by analysts from $39.21 to $43.64, with forecasts ranging from $18 to $100 per share. This new target suggests a potential upside of approximately 195% based on the August 13 closing price. …

Deutsche Euroshop-Aktie stabil: Gewinn im ersten Halbjahr gestiegen

Eurofins Scientific: Director/PDMR Shareholding

LUXEMBOURG, August 14, 2026--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse …

Euroseas (NASDAQ: ESEA) delivers strong Q2 profit, boosts adjusted EPS and keeps $0.80 dividend

Euroseas Ltd. reported strong financial results for Q2 2026, including a net profit of $32.6 million and an increase in Adjusted basic EPS to $9.45 for the first half of the year. The company declared a quarterly dividend of $0.80 per share and highlighted …

Q3 Earnings Forecast for Neurogene Issued By HC Wainwright

Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33

Chardan Capital has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and increased its price target to $33. This positive outlook suggests continued confidence in the company's prospects.

Short Interest in EuroDry (NASDAQ:EDRY) Increases By 154.5%

EuroDry (NASDAQ:EDRY) saw a significant increase in short interest, rising by 154.5% to 11,188 shares by July 31st, although this represents only 0.4% of outstanding shares. The company recently reported a strong quarterly earnings beat, with EPS of $2.44 against a $1.23 consensus, and …

Stoneweg Europe Stapled Trust (SGX:SET) Stock Yield Faces Cash Coverage Strain

Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths

Neurocrine's drug, Vykat XR, designed to treat the insatiable appetite associated with Prader-Willi Syndrome (PWS), is facing safety warnings following seven deaths. Patient organizations and doctors are calling for more research into the drug's safety, emphasizing that PWS patients often have multiple other health …

Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research has downgraded Minerva Neurosciences (NASDAQ:NERV) to a "strong sell" rating, citing weak earnings forecasts despite the company beating Q2 analyst expectations. The biopharmaceutical company's shares opened at $3.92, significantly below its 52-week high, and institutional investors hold a 34.56% stake. Analysts project …

US$6.00 - That's What Analysts Think Neuronetics, Inc. (NASDAQ:STIM) Is Worth After These Results

Neuronetics, Inc. (NASDAQ:STIM) recently reported quarterly results showing better-than-expected revenues of US$42m and smaller statutory losses of US$0.05 per share. Analysts have largely maintained revenue forecasts for 2026 at US$161.8m but significantly reduced loss per share estimates to US$0.35. The average price target has …

Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages

Minerva Neurosciences, Inc (NASDAQ:NERV) has received a "Reduce" consensus rating from brokerages, with an average 12-month price target of $10.50. This comes as near-term earnings expectations have significantly deteriorated, with HC Wainwright cutting its fiscal 2026 and 2027 EPS estimates, although it projects profitability …

Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants

Balyasny Asset Management L.P. and its affiliates have reported a beneficial ownership of 9.99% in Minerva Neurosciences, Inc. (NERV). This stake comprises 4,654,212 shares, including 4,257,000 shares held directly by Atlas Private Holdings (Cayman) Ltd. and 397,212 shares exercisable from 13,500 warrants. The warrants …

Euro Panel Products Q1 Results: Net profit falls 13% YoY to ₹495 lakh

EuroDry (EDRY) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Monday, Aug. 10, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Financial Officer - Anastasios AslidisFinance Manager - Athina Atalioti TAKEAWAYS Total Net Revenues -- $17.7 million for the second quarter, representing a 57% increase compared to the …